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In this paper we describe a receptor for C4b on human peripheral B lymphocytes 
and cultured human lymphoblastoid cells. The C4b receptor was demonstrated 
by rosette formation  with EAC14.  We also found that  this  receptor cooperates 
with the C3b receptor in the binding of antigen-antibody complement complexes 
to lymphocytes. A preliminary report of this work was presented in the form of an 
abstract  (1). Independently, Ross and Polley (2)  recently presented evidence for 
the  presence  of  such  a  receptor  on  polymorphonuclear  leukocytes  and  B 
lymphocytes.  The  occurrence  of  a  C4b  receptor  on  human  erythrocytes  was 
originally  described  by  Cooper  (3)  who  observed  C4b-dependent  immune 
adherence. 
Human peripheral B lymphocytes have receptors for IgG Fc {4-6), receptors for 
C3b (7,  8) and C3d (9), and membrane-bound IgG, which presumably functions 
as receptor for antigens.  Although these receptors are useful for the characteriza- 
tion of cells, more important is their biologic role. IgG Fc, C3b, and C3d receptors 
mediate  contact  between  antigen-antibody  complement  complexes  and  cells 
bearing  these  receptors.  After  contact,  monocytes  (10),  macrophages  (7),  and 
polymorphonuclear  leukocytes  (11)  engulf and  digest  such  complexes.  It  was 
shown that IgG Fc and C3b receptors on monocytes (10) and polymorphonuclear 
leukocytes  (2)  cooperate  in  the  phagocytosis  of immune  complexes.  Another 
function  of  C3b  receptors  was  demonstrated  in  an  earlier  report  from  this 
laboratory.  C3b bound to C3b receptors of Raji cells, which are cultured human 
lymphoblastoid  cells  derived  from  a  patient  with  Burkitt's  lymphoma,  lysed 
these cells through  activation of the alternate  complement pathway  (12,  13). 
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Peripheral  Blood Lymphocytes.  Peripheral blood lymphocytes were prepared from defibrinated 
blood of healthy donors by sedimentation in 1% Dextran and centrifugation on Isopaque Ficoll as 
described earlier (12).  Macrophages were removed by either incubation of the cells in plastic dishes 
and separation of the nonadhering cells or by carbonyl iron ingestion and separation in a magnetic 
field. The lymphocyte preparations obtained with these procedures contained 94-97%  lymphocytes. 
Lymphoblastoid  Cell Lines.  The cell lines used in this study were kindly provided by Dr.  F. 
Jensen  and  Dr.  A.  N.  Theofilopoulos, Scripps  Clinic.  Raji  cells  were  derived from  a  Burkitt's 
lymphoma patient (14, 15), and Wil2WT cells from the spleen of a patient with hereditary spherocytic 
anemia (16). SCRF 5001 are cultured from peripheral blood lymphocytes  of SLE patients, 1454-9 cells 
are embryonic lymphocytes derived from the placenta of a patient with SLE. Sommer B 8432 cells are 
cultured from the peripheral blood of a patient with acute lymphocytic leukemia. 
EAC Intermediate  Complexes.  EAC complexes were prepared with isolated human complement 
components. C1,  C2,  C3,  and C4 were isolated from human serum according to published methods 
(17). For the preparation of EAC 14, 1 x  109 sheep erythrocytes sensitized with rabbit anti-erythrocyte 
antibody were incubated with purified C1  for 20  min at  37°C,  then washed at 37°C with GVB ~ 
(Veronal-buffered  saline containing 0.1% gelatin, 1.5 x  10-' M calcium and 5 x  10  ~  M magnesium). 
EAC1 were then incubated with varying amounts of C4,  ranging from 1 ~g to 100 ug, for 30 min at 
37°C. EAC14 were washed in cold GVB and stored at 4°C at a concentration of 1 x  10 ~  cells per ml. In 
order to produce EAC1423,  EAC14 cells were again incubated with C1 for 15 min at 37°C, washed, 
and reacted with an excess amount of C2  for 30  rain  at 32°C. After washing, EAC142  cells were 
incubated with varying amounts of C3, ranging from 1 lzg to 100 ~g for 20 min at 30°C. EAC1423  were 
washed in cold GVB and stored at 4°C at a concentration of 1 x  109 cells per ml. For the quantitation 
of molecules per cell, ~25I-labeled C3 or C4 were used. 
Radioiodination  of C3 and  C4.  C3  and  C4  were labeled with  ~51  according to the method of 
McConahey and Dixon (18). 
Fragments of C3 and  C4.  C3b, a  fragment of C3,  was produced by cleaving C3 either with the 
complement enzyme C~  or trypsin {19). C4b, a  fragment of' C4, was produced by treatment of C4 
with Cls or trypsin (20). 
Rosette Assay.  5 x  105 peripheral lymphocytes were incubated with 1 x  107 EAC in a total vol of 
0.4 ml minimal essential medium (MEM) containing 5% fetal calf serum and 0.01 M EDTA. The cell 
mixture was incubated for 30 min at 37°C in a CO9 incubator. The percent of rosette-forming cells 
(three or more bound EAC per lymphocyte) was determined by viewing at least 300 lymphocytes in a 
hemocytometer using  a  Leitz  phase  microscope (E.  Leitz,  Inc.,  Rockleigh,  N.  J.).  In  inhibition 
experiments various amounts of inhibitor were added to the cell mixture at the start of the incubation 
period. 
Immune Adherence.  Immune adherence experiments were performed in microtiter plates (Cook 
Engineering Co.,  Alexandria,  Va.).  Each  well  was  filled  with  25  #l  of Veronal-buffered saline 
containing 0.1% human serum albumin, pH 7.5 (SAVB). Then 25 pl of 1 x  109 EAC was placed in the 
first well and diluted serially. Thereafter, 25 ~l  SAVB and' 25 ~l of 6  x  107 human blood group O 
erythrocytes were added to all wells. The cells were incubated for 30 min at 37 °C, after which time the 
sedimentation pattern was evaluated. For inhibition experiments the highest dilution of EAC giving 
an agglutination pattern was chosen. In  a  typical inhibition experiment, all  wells received 25  lzl 
SAVB, then 25 ~l of inhibitor was added to the first well and diluted serially. Thereafter, 25 ul of EAC 
suspension and 25 ul of 6  x  10 ~ human blood group O erythrocytes were added to all wells and the 
plates were incubated for 30 min at 37°C and evaluated. 
Removal  of  Rosette-Forming  Lymphocytes  by  Albumin  Gradient  Centri[ugation.  Albumin 
gradient centrifugation was performed according to the method described by Bianco et al.  (8). 
KAF Treatment  of EAC14 and  EAC1423.  KAF (C3b inactivator) was kindly provided by Dr. 
Cooper, Scripps Clinic. 1 x  l0 g EAC14 and EAC1423  were incubated with KAF for 60 min at 37°C. 
Thereafter, the treated cells were examined for immune adherence reactivity. 
1  Abbreviations  used  in this paper:  GVB,  Veronal-buffered saline containing 0.1% gelatin, 1.5  x 
10 -~ M  calcium and 5  x  10 -' magnesium; SAVB, Veronal-buffered saline containing 0.1% human 
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Results 
Demonstration  of  a  C4b  Receptor  on  Human  Peripheral  B  Lymphocytes. 
While  studying the  C3b  receptor on human  peripheral  B  lymphocytes, it  was 
noticed  that  certain  batches  of EAC14  used  as  controls formed rosettes with 
virtually the  same  number of' lymphocytes as  did EAC1423.  This observation 
suggested the presence of a  receptor for C4b on lymphocytes. Table I compares 
the  percentage  of lymphocytes of several healthy blood  donors  which  formed 
rosettes  with  EA,  EAC14,  and  EAC1423.  Virtually  the  same  percentage  of 
lymphocytes formed rosettes with  EAC14  (14.4%)  and  EAC1423  (13.5%).  Only 
2.8% lymphocytes formed rosettes with EA. Approximately the same number of 
lymphocytes  forming  rosettes  with  EAC14  also  interacted  with  EAC142  or 
EA C 14oxy2. 
The observation that a comparable number of lymphocytes in each preparation 
TABLE  I 
Receptors for C4b on Hum.an Peripheral Lymphocytes 
Lymphocyte Donors 
Rosette-forming  lymphocytes 
EA  EAC14  EAC1423 
%  %  % 
H.S.  1  16  14 
M.G.  6  15  17 
E.S.  0  16  15 
P.U.  3  14  13 
A.S.  4  12  7 
M.Y.  1  9  7 
P.B.  5  19  22 
Average  2.8  14.4  13.5 
formed rosettes with EAC14 and  EAC1423 suggested that it was the same cell 
population  which  interacted  with  both  intermediate  complexes.  This  was 
demonstrated by two different methods:  (a)  1 ×  107 intact EAC14 and  1 x  107 
lysed  EAC1423  were  incubated  together with  5  ×  105  lymphocytes. Rosettes 
consisting of lymphocytes and both intermediate complexes were observed under 
phase  microscopy.  (b)  Reduction  of the  number  of EAC1423  rosette-forming 
lymphocytes in a lymphocyte preparation also diminished the number of EAC 14 
rosette-forming  lymphocytes.  In  these  experiments,  one  batch  of  1  x  107 
lymphocytes was first allowed to form rosettes with 2 x  108 EAC1423. EAC1423 
were prepared from EAC14 containing a low number of' C4b sites per cell which 
per  se  did  not  induce  rosette  formation.  As  controls,  one  batch  of  1  ×  107 
lymphocytes was  incubated with 2  x  108 EAC1  and another batch in medium 
alone.  Subsequently,  the  three  batches  of  lymphocytes  were  subjected  to 
centrifugation in a 23-33% bovine serum albumin gradient, in which rosettes and 
erythrocytes are pelleted and the free lymphocytes remain in the upper portion of VIKTOR A. BOKISCH AND ALAIN T. SOBEL  1339 
the gradient. These lymphocytes were subsequently analyzed for their ability to 
form rosettes  with either EAC14  or EAC1423.  The results of a  representative 
experiment are graphed in Fig.  1.  In the batch of lymphocytes which had been 
incubated with EAC1423, the number of both EAC1423 lymphocyte rosettes and 
EAC14 lymphocyte rosettes was significantly reduced. The results obtained show 
that the receptors for C4b and C3b  are present on the same cell. Furthermore, 
staining of lymphocytes with fluorescein-conjugated antihuman IgG showed that 
EAC14  as  well  as  EAC1423  rosette-forming cells  have  membrane-bound  Ig, 
characterizing these cells as B-type lymphocytes. 
Exclusion of Traces of C3b on EAC14.  Since it was suggested that only 60- 
100 C3b molecules per EAC1423 are required for immune adherence (3), it had to 
be  excluded  that  EAC14-forming rosettes  with  lymphocytes contained  trace 
amounts of C3b.  To assess whether EAC14 had taken up traces of C3b,  EAC14 
was prepared with C4 which was purposely contaminated with ~sI-labeled C3, in 
E 
-~10. 
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EAC1423 
EAC1423 
Lymphocytes  Lymphocytes  Lymphocytes 
+ EAC1  + EAC1423 
Fm.  1.  EAC14 and EAC1423 rosettes after removal of EAC1423 lymphocyte rosettes fromthe 
lymphocyte preparation, 
two separate experiments. In the first experiment, batch (a) was incubated with 
15 ttg of C4 alone, batch (b) with 15 ttg C4 and 15 ttg [1~I]C3, and batch (c) with 
15  ttg  [125I]C3 alone. The  second experiment followed the  same  protocol with 
the  exception that,  instead  of 15  ttg,  30  #g  of each  component was  used.  All 
complement-cell complexes were  analyzed for the  presence  of C3b  by hemag- 
glutination with rabbit antihuman C3 and by measuring uptake of radiolabeled 
C3.  The results of these experiments are  summarized in Table II. None of the 
intermediate  complexes  was  agglutinated  with  anti-C3.  EAC1  which  was 
incubated with either C4 alone or with C4 and [12~I]C3 agglutinated strongly with 
antihuman  C4,  demonstrating  the  presence  of  C4  on  those  cells.  In  both 
experiments, EAC1  incubated with C4  and  [12~I]C3 and EAC1 incubated with 
[125I]C3 alone bound the same number of C3 molecules suggesting that C3 was 
bound nonspecifically. Furthermore, there was no difference in  [12~I]C3 uptake 
between the two experiments which differed in the amounts of C4 and  [125I]C3 1340  RECEPTOR FOR THE FOURTH COMPONENT OF COMPLEMENT 
TABLE II 
Analysis of EAC14 for the Presence  of C3b 
Hemagglutination  No. of C3 
Treatment of EAC 1  Rosette  Immune  with:  or C3b 
cells*  formation  adherence  molecules 
Anti-C3  Anti-C4  per cell 
15#g C4  +/  0  0  0  +  0 
15~gC4  +  t5pg [125I]C3  0  0  0  +  46 
/  +  15ug ['~I] C3  0  0  0  0  46 
30 ug C4  + /  +  +  0  +  0 
30#g C4  +  30#g [125I] C3  +  +  0  +  50 
/  +  30pg [125I]C3  0  0  0  0  45 
* 1  ×  10 ~ EAC1 cells were incubated with C4 and/or C3 in a  total vol of 0.5  ml. 
used. The results demonstrate that binding of EAC14 to lymphocytes or erythro- 
cytes is mediated by C4b. When tested in the rosette assay or immune adherence, 
intermediate  complexes  prepared  with  15  #g  C4  were  negative,  whereas  the 
intermediate complexes prepared with 30 ug of C4 were positive. The observation 
that  only  EAC14  cells  prepared  with  30  #g  of C4  were  positive  in  immune 
adherence and rosette formation suggested a dose dependency of this phenome- 
non. 
Dose  Response  of  C4b  and  C3b  Rosette  Formation  and  Immune 
Adherence.  To measure the  C4 dependence of rosette formation and immune 
adherence,  EAC14  with  a  defined number of  [125I]C4b molecules per cell was 
used.  For  comparison,  EAC1423  with  a  comparable  number  of  [12sI]C3b 
molecules per cell was also tested in both assays. The results of this experiment 
which are depicted in Fig. 2 show that more than 4,000 C4b molecules per cell are 
required to produce a maximal number of rosettes. EAC1423 containing less than 
1,000 C4b molecules per cell needed at least 2,000 C3b molecules per cell in order 
to produce maximal rosette formation. The immune adherence reactivity of the 
two different types of intermediate complexes roughly paralleled their rosette- 
forming ability. 
To investigate whether C3b and C4b cooperate in the rosette-forming function, 
the following experiment was performed. Two batches of EAC14 were prepared, 
one containing 350 molecules of C4b per cell and the other 5,500 C4b molecules 
per cell. Samples of these preparations were then reacted with C2 and C3, such 
that the number of bound C3b molecules varied in different samples between 0 
and 2,100 per cell. Fig. 3 shows the percentage of rosette formation as a function 
of cell-bound C3b. 
The apparent  rosette-forming ability of cells with a  small  number of bound 
C4b molecules is entirely dependent on the presence of a relatively large number 
of  C3b  molecules.  Rosette  formation  by  cells  with  a  large  number  of  C4b 
molecules  is  independent  of,  however,  increases  by  cell-bound  C3b.  In  this 
particular experiment the  same  percentage of rosette formation was  observed 
with either 5,500 C4b molecules per cell or 350 C4b plus 1,500 C3b molecules per VIKTOR A. BOKISCH AND ALAIN T. SOBEL 
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Cooperation of C3 and C4 in lymphocyte rosette formation. 
cell.  These  results  suggest  that  C3b  is  more  efficient than  C4b  or that  both 
fragments act cooperatively in the binding of EAC 1423 to human lymphocytes. 
Characterization  of  C3b  and  C4b  Receptors  as  Identical  or  Distinct 
Entities.  Since C3b and C4b  bind to the same cells, the question arose as to 
whether these cells have one receptor which binds both ligands or, alternatively, 
two different receptors, one specific for C3b and the other for C4b. To distinguish 
between the two possibilities, we tried to inhibit EAC14 lymphocyte rosettes with 
soluble C3b or C4b. The results depicted in Fig. 4 show that the same degree of 
inhibition was obtained with equal amounts of C3b or C4b. EAC1423 lymphocyte 
rosettes  are  also  inhibited  by equal  amounts  of either protein.  These  results 
suggest that human B lymphocytes have a single receptor capable of' binding C3b 
and C4b. 1342  RECEPTOR FOR THE FOURTH COMPONENT OF COMPLEMENT 
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Inhibition of EAC14  lymphocyte rosettes by C3b or C4b. 
To inhibit immune adherence of EAC14 or EAC1423 to human e~throcytes an 
approximately  300-fold  excess  of  free  over  bound  C3b  or  C4b  was  needed. 
Considerably  more  free overbound molecules were required  to  inhibit  lympho- 
cyte rosette formation with either intermediate complex. As shown in Fig. 4,  160 
pg of C3b or C4b resulted in 60% inhibition of' rosette formation. Since EAC14 
intermediates  used in  this  experiment contained 5,500  C4b  molecules per cell, 
the molar ratio of bound C4b to free C4b or C3b was approximately 1 to 10,000. In 
spite of the large amount of inhibitor required, the inhibition was specific since 
the same amount of albumin  or IgG was not inhibitory. 
In contrast to the inhibition experiment which suggested a  single receptor for 
C3b  and  C4b,  evidence for a  C3b  receptor distinct  from the  C4b  receptor was 
found by testing several human lymphoblastoid cell lines for their ability to form 
rosettes  with  EAC14  or  with  EAC1423.  Table  III  shows  that,  of all  cell  lines 
tested,  fewer cells  formed rosettes with  EAC14  than  with EAC1423.  Raji  cells 
formed rosettes only with EAC1423 and not with EAC14. As shown in Fig. 5, no 
rosettes  were  observed  even  when  EAC14  was  used  containing  14,000  C4b 
molecules per cell, whereas approximately 65% of Raji cells formed rosettes with 
EAC1423 containing the same number of C3b molecules per cell. 
Lack of Receptors/or KAF-Treated C4b  on Human Peripheral  Lymphocytes 
and Erythrocytes.  Cooper  2 demonstrated that  KAF  (C3b  inactivator)  cleaves 
cell-bound C4b in a manner similar to cell-bound C3b. Following KAF treatment 
of cell-bound C4b, a portion of the molecule (C4d) analogous to C3d remains cell 
bound, whereas the remainder of the C4b molecule is dissociated from the cells. 
Because C3d reacts with human lymphocytes and certain cultured lymphoblas- 
toid cells, a (9,  21)  we tested whether human B  lymphocytes have receptors for 
C4d. EAC14 and EAC1423 were incubated with purified KAF for 60 rain at 37°C, 
washed, and then used in the rosette test with human peripheral lymphocytes. As 
control, the same intermediate complexes were incubated with NaC1. As shown 
2  Cooper, N. R. Manuscript in preparation. 
3  Theofilopoulos, A. N., C. B. Wilson, F. J. Dixon, and V. A. Bokisch. Binding of soluble immune 
complexes to human lymphoblastoid cells. II.  Use of Raji  cells to detect circulating immune com- 
plexes in animal and human sera. J. Exp. Med. 140:1230. VIKTOR A. BOKISCH  AND ALAIN  T. SOBEL 
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Cell lines 
Rosette-forming  cells 
EA  EAC14  EAC1423 
%  %  % 
Wil2 Wt  5  1  7 
SCRF 5001  6  8  38 
1454-9  0  15  45 
Sommer B 8432  5  39  70 
Raji  2  1  82 
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Fro. 5.  Dose  response of C4 or C3 in rosette formation of Raji cells with EAC14  or EAC1423. 
in Fig. 6, KAF treatment of the intermediate complexes significantly reduced the 
number of EAC14 lymphocyte rosettes,  while only a slight reduction of EAC1423 
lymphocyte rosettes  was  observed.  These  results  indicate  that  KAF treatment 
abolishes the binding site of cell-bound C4b and, that human lymphocytes lack a 
receptor for C4d. 
Discussion 
This  report  describes  a  receptor for C4b on peripheral  human  B  lymphocytes. 
The receptor reacts with red cell-bound C4b (EAC14) as well as with soluble C4b. 
The  presence  of a  C4b  receptor on erythrocytes has  previously been  shown by 
Cooper (3)  who demonstrated that EAC14 cells produced the immune adherence 
phenomenon with human erythrocytes. Recently, Ross et al.  described a similar 
receptor on  human  polymorphonuclear leukocytes  (2).  Since  it  was  previously 
shown  that;  only  60-100  C3b  molecules  per  EAC1423  cell  were  needed  for  a 
positive immune adherence reaction with human erythrocytes (3),  the presence 
of minute amounts of C3b on EAC14 cells had to be excluded. For this purpose, 
known  amounts  of  ['25I]C3 were  added  to  C4  preparations  and  C3  uptake  on 
EAC14 was  measured.  In  several  experiments  using  different  amounts  of C4, 1344  RECEPTOR FOR THE FOURTH  COMPONENT OF COMPLEMENT 
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on  EAC14 and  EAC1423 lymphocyte  rosette 
purposely contaminated with C3, we found no uptake of specifically bound C3 by 
EAC14 which could account  for their interaction  with  human  erythrocytes or B 
lymphocytes. 
The question whether the C4b receptors are distinct from the C3b receptors on 
human  erythrocytes  and  B  lymphocytes  remains  unresolved.  The  observation 
that both C3b and C4b inhibit EAC14 and EAC1423 lymphocyte rosettes and the 
immune  adherence  reaction  of  both  intermediate  complexes  with  human 
erythrocytes suggested that the C4b and C3b receptors are either identical or are 
different  entities,  exhibiting  cross  specificity  for  the  other  ligand.  Receptors 
which bind more than one type of ligand have been described. For example, C3b 
receptors  on  Raji  cells  (12)  and  other  human  lymphoblastoid  cells  bind,  in 
addition to human C3b, native C3, as well as C3b and C3 of other species 3 (21). 
Furthermore, recent studies revealed a striking similarity between C34 and C45 
(19,  20).  In the  course of complement activation,  C3 and  C4 are cleaved by the 
complement  enzymes  C3  convertase  and  C1  esterase,  respectively,  into  a  low 
molecular  weight  a  fragment and  a  large  b  fragment.  Upon  cleavage,  C3b and 
C4b acquire two binding sites, a labile binding site which allows the molecules to 
attach  themselves  to  cell  membrane  surfaces,  immune  complexes  and  other 
particles, and a  stable binding site which enables C3b and C4b to react with C3b 
or C4b receptors on the surface of various cells. Both molecules are also suscepti- 
ble to the action of KAF, or C3b inactivator. 2 
In contrast to human peripheral lymphocytes, which formed the same number 
of rosettes with EAC14 and EAC1423,  cultured human lymphoblastoid cells gave 
fewer  rosettes  with  EAC14  than  with  EAC1423.  More  importantly,  Raji  cells 
formed rosettes only with EAC1423, demonstrating that these cells lack receptors 
for C4b  and  that  the  C3b  receptors on these  cells do not  cross-react with  C4b. 
These  results  may  suggest  that  the  receptors  for  C3b  and  C4b  are  distinct 
entities.  However,  since  cells  in  culture  alter  some  of  their  properties,  it  is 
' Bokisch, V. A. and H. J. Mtiller-Eberhard. Manuscript  in preparation. 
Schreiber, R. D. and H. d. Mfiller-Eberhard. Fourth component of human complement: descrip- 
tion of the three polypeptide chain structure. J. Exp. Med. 140:1324. VIKTOR A. BOKISCH AND ALAIN T. SOBEL  1345 
conceivable that receptors of cultured cells may have changed their specificity, or 
may have been lost. 
Since  KAF  cleaves  C4b ~ as  well  as  C3b  (22, 23),  rendering  EAC14  and 
EAC1423  unreactive  in  immune  adherence  with  human  erythrocytes,  we 
investigated whether such treatment exposed  a  new  binding site  on  the  C4b 
molecule analogous to the C3d binding site which appears after KAF treatment 
of EAC1423. Peripheral human lymphocytes (9)  and lymphoblastoid cells  3 (21) 
have a receptor for C3d. The fact that KAF-treated EAC14 did not form rosettes 
with peripheral human lymphocytes indicates that lymphocytes lack a receptor 
for KAF-treated C4b (C4d). 
Cell-bound C4b and C3b cooperate in the binding of EAC1423 to C3b and C4b 
receptor bearing cells. This was demonstrated by lymphocyte-rosette formation 
with various EAC1423, prepared from two batches of EAC14 cells differing in the 
amount of cell-bound C4b. In these experiments, the number of cell-bound C3b 
molecules required to give a maximal number of rosettes was significantly lower 
for  EAC1423  containing  a  large  number  of  C4b  molecules  as  compared  to 
EAC1423 with few C4b molecules per cell, indicating a cooperative effect of C3b 
and C4b. Because of the cooperation of C3b  and C4b  in EAC1423-1ymphocyte 
rosette formation or immune adherence reactions the number of cell-bound C4b 
has to be taken into account in estimating the number of cell-bound C3b required 
for the binding of EAC1423 to receptor-bearing cells. Indeed, the discrepancy in 
the  numbers of C3b  on  EAC1423  needed for immune adherence between our 
results and those of others may be due to different amounts of C4b per EAC1423. 
It  has  been  shown that the  receptor  for C3b  is  essential  in phagocytosis of 
antigen-antibody complement complexes. The C3b receptor on phagocytic cells 
such as monocytes or polymorphonuclear leukocytes and macrophages mediates 
contact between these complexes and the cells. Huber et al. (10) have shown that 
binding of antigen-antibody complexes without complement to phagocytic cells 
is inhibited by physiologic amounts of IgG. Binding of complexes, however, can 
be mediated by C3b even in the presence of IgG. In a model system, using Raji 
cells  which  have  receptors  for IgG  Fc  and  C3b,  we  could  show  that  human 
aggregated IgG which has interacted with complement bound to these cells only 
through the complement receptors for C3b  and C3d. 3 In the present report we 
show that C4b like C3b mediated the binding of antigen-antibody complement 
complexes to human B lymphocytes and human erythrocytes via C4b receptors 
on these cells.  Similar receptors  are present on polymorphonuclear leukocytes 
(2).  We have preliminary evidence for the presence of C4b receptors on human 
monocytes. Since attachment of immune complexes to phagocytic cells is mostly 
followed by phagocytosis of these complexes, it is evident that the C4b receptor 
plays  a  role  in  immune  clearance  of such  complexes.  The  reduced  immune 
clearance  of immune  complexes  in  C4-deficient  guinea  pigs  as  compared  to 
normal animals may exemplify the contribution of C4b to this mechanism (24). 
Summary 
This report describes receptors for C4b on human peripheral B lymphocytes. The 
simultaneous presence of C3b  and C4b receptors on the same lymphocytes was 1346  RECEPTOR FOR THE FOURTH COMPONENT OF COMPLEMENT 
demonstrated by the formation of mixed rosettes consisting of' the lymphocytes, 
EAC14  and  EAC1423.  Furthermore,  reduction  of  the  number  of  EAC1423 
rosette-forming lymphocytes in  a  lymphocyte population  by albumin  gradient 
centrifugation  concomitantly  reduced  EAC14  rosette-fbrming  lymphocytes. 
Binding  of  EAC14  intermediates  to  receptors  on  human  lymphocytes  and 
erythrocytes  could  be  inhibited  by  equal  amounts  of  soluble  C3b  or  C4b, 
suggesting  the  presence  of a  single  receptor  for both  ligands  on those  cells.  In 
contrast,  the  results  of  the  rosette  assay  with  Raji  cells,  cultured  human 
lymphoblastoid cells,  EAC14 and EAC1423 suggested that the receptors for C4b 
and C3b are distinct entities, since Raji cells formed rosettes with EAC1423, but 
not  with  EAC14.  Moreover,  this  report  demonstrates  a  cooperation  of  eryth- 
rocyte-bound  C4b  and  C3b  in  the  binding  of EAC1423  to  B  lymphocytes.  In 
contrast to KAF-treated C3b,  KAF-treated C4b did not bind to B  lymphocytes, 
indicating that these cells lack a  receptor for C4d. 
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